Therefore, administering anti-TGF-β therapies by this time could block one of the most important molecular pathways that sustain cancer cells mesenchymal phenotype, inducing MET and facilitating the growth of secondary tumors (Figure 1). This evidence concerns the gene TGFB1 and cancer.